GLP-1 Drugs, Muscle Loss and the New Role of Smartwatches
GLP-1 muscle loss monitoring with smartwatches refers to the use of wearable devices to track body composition, activity and related biometrics in people taking GLP-1 weight-loss medications, with the goal of spotting and preventing loss of muscle mass rather than focusing only on total weight change. GLP-1 drugs such as Ozempic are effective for weight control and Type 2 diabetes, but doctors are increasingly worried about unintended effects on muscle. According to Dr David N. Brennan of the Mayo Clinic, more than 30 per cent of the weight lost while using GLP-1 drugs may come from muscle tissue. As use of these medications grows, technology companies see an opening: smartwatch health monitoring that goes beyond step counts to track how healthy, functional weight is changing over time.
Inside Samsung’s Galaxy Watch 8 Muscle-Protection Study
Samsung is partnering with the Massachusetts General Hospital Diabetes Research Centre to test whether the Galaxy Watch 8 can help reduce GLP-1 muscle loss. The study follows 100 adults starting GLP-1 treatment, splitting them into two groups. One group receives standard guidance usually given to GLP-1 users. The other wears a Galaxy Watch 8 connected to Samsung Health for wearable muscle tracking and coaching. The watch uses Bioelectrical Impedance Analysis to estimate body composition and continuously records physical activity and heart rate. Clinical-grade DXA scans will provide precise baseline and follow-up body composition data so researchers can compare both groups. The aim is not to replace clinical care, but to see if continuous smartwatch health monitoring can support decisions between clinic visits and encourage exercise habits that protect muscle while weight is coming off.
Why Muscle Loss Matters More Than the Number on the Scale
Weight-loss success is often described in kilograms, but for GLP-1 users the quality of that weight loss is critical. Muscle, especially axial muscle along the spine and trunk, underpins posture, balance and everyday movement. Researchers have warned that losing lean body mass during GLP-1 treatment could raise cardiovascular risk and lower long-term quality of life. There is also concern that some people may not regain lost muscle even if they later regain fat after stopping the drug, which can lower basal metabolic rate and make future weight regain more likely. As Dr Melissa Putman notes, many GLP-1 patients struggle with muscle mass loss, a common side effect that can increase cardiovascular risk and reduce basal metabolic rate. Protecting muscle has become a core clinical goal rather than a cosmetic concern.
From Fitness Tracker to Preventative Health Tool
The Samsung study marks a broader shift in Galaxy Watch health features from casual fitness tracking toward preventative health monitoring. Instead of showing only daily steps or calories, the watch in this trial supplies body composition estimates, activity profiles and heart rate trends that can be linked to GLP-1 treatment timelines. Continuous data gives clinicians a more complete view between appointments, making it easier to flag patterns that might signal rising GLP-1 muscle loss risk, like falling resistance training minutes or declining active time. Samsung says the study is meant to test how wearable data can be combined with clinical care, not run in parallel. If successful, similar smartwatch health monitoring approaches could extend to other long-term treatments, turning wearables into everyday tools for maintaining strength and function, not just hitting fitness goals.
What This Means for the Future of Wearable Muscle Tracking
Samsung’s work with Massachusetts General Hospital fits into a growing trend of linking wearables with medical research. Past collaborations included sleep apnoea detection research with Stanford University and fainting prediction work with Chung-Ang University Gwangmyeong Hospital, showing how biometric streams can support condition-specific insights. GLP-1 drugs are now used by a large share of adults, and demand is rising for tools that track side effects in real time. If the Galaxy Watch 8 trial shows that wearable muscle tracking can help preserve lean mass, it could accelerate efforts to embed devices into routine care plans. Analysts expect AI and biometric data to make wearables more central in healthcare, but experts caution that more clinical studies are needed before smartwatch health monitoring becomes a standard part of GLP-1 therapy.